Xenetic Biosciences is trading $2.60 (-6.14%) amid volatility following the proposed all-stock Santersus acquisition, after closing at $2.77 on September 18. - No new September 21 company announcement or clear overnight catalyst was identified. - Existing shareholders would retain approximately 15% of the combined company. - S&P 500, Nasdaq Composite, and Dow Jones are higher pre-market, so weakness does not appear to reflect overall risk sentiment.